DLL3 has been found to be highly expressed in SCLC-A and SCLC-N subtypes and it should be of interest to evaluate whether DLL3-targeting therapies achieve better outcomes in this setting [52]. This evidence concerns the gene DLL3 and small cell lung carcinoma.